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  50 
Abstract 51 
 52 
Background  53 
An imbalance between cellular antioxidant defense system(s) and reactive oxygen species 54 
(ROS)-driven oxidative stress has been implicated in the pathogenesis of inflammatory bowel 55 
disease. Peroxiredoxin (PRDX) 6, contributes to an appropriate redox balance by clearing 56 
ROS and reducing peroxidized membrane phospholipids. 57 
 58 
Aims 59 
We here studied the role of Prdx6 in acute and chronic DSS-induced colitis. 60 
 61 
Design  62 
To investigate the impact of PRDX6 on intestinal inflammation, we used wild type (WT), 63 
Prdx6 knock-out mice (Prdx6-/-) and transgenic mice (Prdx6tg/tg), overexpressing Prdx6. 64 
Acute and chronic colitis was induced by dextran sulfate sodium (DSS) in WT, Prdx6-/-, and 65 
Prdx6tg/tg mice. Colitis was evaluated by endoscopy, colon length, histopathological 66 
assessment, and myeloperoxidase (MPO) activity. Changes in mRNA and protein expression 67 
of pro-inflammatory cytokines and antioxidant enzymes were evaluated by RT-qPCR and 68 
western blot. Total GSH levels in colon samples were determined.  69 
 70 
Results  71 
Prdx6-/- mice exposed to acute and chronic DSS showed a significant decrease in the clinical 72 
parameters and in colonic expression of pro-inflammatory cytokines compared to WT mice. 73 
mRNA expression of antioxidant enzymes in colon samples was significantly increased in 74 
Prdx6-/- compared to WT mice exposed to acute and chronic DSS. In addition, total GSH 75 
levels were increased in Prdx6-/- mice treated with DSS in comparison to WT. Overexpression 76 
of Prdx6 did not significantly influence acute and chronic colitis.  77 
 78 
Conclusion 79 
Our data indicate that a lack of the antioxidant enzyme PRDX6 protects against the 80 
development of acute and chronic experimental colitis and is associated with increased 81 
expression and function of other antioxidant enzymes suggesting effective compensatory 82 
mechanisms.  83 
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  87 
Introduction  88 
The major forms of inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative 89 
colitis (UC), are chronic, relapsing inflammatory disorders of the gastrointestinal (GI) tract 90 
causing a life-long burden on affected patients (1). Both disorders have a multifactorial 91 
pathogenesis with three main factors involved in their pathogenesis: environmental exposure 92 
(e.g. to gut microbiota and microbial pathogens), genetic susceptibility (e.g. predisposing 93 
factors affecting the gut barrier function) and consecutive dysregulation of the immune 94 
system (on the innate and adaptive level) (2-3).  95 
The mechanisms by which imbalances of the immune system initiate and perpetuate intestinal 96 
damage and inflammation are not entirely clear. However, inflammatory conditions lead to an 97 
increased oxidative burden due to the release of reactive oxygen species (ROS) by activated 98 
macrophages and neutrophils as a part of the body’s defense mechanisms (4). Low levels of 99 
ROS have a protective effect by activating protective signaling pathways against 100 
inflammation and by modulating the immune-mediated attack against extrinsic pathogens. 101 
Conversely, high levels of ROS create oxidative stress within the cells and, in case of chronic 102 
exposure, changes in the genome, such as single strand DNA breaks, sugar moiety 103 
modifications, and deamination and adduction of bases (5), leading to a loss of homeostasis 104 
(6).  105 
Several studies have established a direct relation between oxidative stress and IBD 106 
pathogenesis in both, human subjects and animals subjected to experimental colitis. Clinical 107 
studies showed an increase of ROS as well as biomarkers of oxidative injury, including lipid 108 
peroxidation products and protein modifications, in the intestinal mucosa of patients with 109 
either UC or CD (7-8). These highly cytotoxic molecules contribute to tissue damage in IBD 110 
(9). In line with this, Barbosa et al., (10) showed a correlation between the activity of free 111 
radicals in the intestinal mucosa of IBD patients, and the clinical disease activity. To maintain 112 
adequate ROS levels, a balance between oxidant and antioxidant mechanisms is necessary. A 113 
depletion of antioxidant levels in the intestinal mucosa and in peripheral red blood cells has 114 
been observed in IBD patients (11-13). Genetic polymorphisms in antioxidant enzymes are 115 
associated with altered enzyme activity and a higher risk of developing IBD (14). In animal 116 
models of IBD, multiple studies demonstrated an increased formation of ROS in the colonic 117 
mucosa (15-16). In line with this, experimental colitis is associated with a decrease in the 118 
levels of endogenous antioxidants in colonic tissue (17). Genetic deletion of ROS-detoxifying 119 
enzymes increases the susceptibility towards tissue destruction (18), whereas an 120 
overexpression of antioxidant enzymes resulted in attenuation of colitis in mice (19-20). 121 
Among the most important antioxidant proteins is the peroxiredoxin (PRDX) family. PRDX6, 122 
a bifunctional 25-kDa protein, is the only member of PRDXs that confers both GSH 123 
peroxidase and phospholipase A2 activities (21). Despite intensive investigations, the role of 124 
PRDX6 in inflammation is still controversial and both protective (experimental autoimmune 125 
encephalomyelitis (22), UV light exposure (23)  wound healing in the skin (24) and 126 
hepatocellular injury in an ischemia-reperfusion model (25)). as well as deleterious effects 127 
(e.g. higher loss of dopaminergic neurons in a model of Parkinsons disease(26)). In order 128 
to elucidate the impact of PRDX6 in intestinal inflammation and, for the first time address its 129 
role in IBD, we induced acute and chronic colitis in Prdx6 deficient or overexpressing mice. 130 
 131 
  132 
Materials and Methods  133 
Patients 134 
Colon and Ileum samples of IBD patients and controls were obtained by colonoscopy as 135 
described previously (27) 136 
Animals 137 
Prdx6 knockout mice (B6.129-Prdx6tm1Pgn/Pgn, here termed Prdx6−/−), with targeted 138 
disruption of the Prdx6 gene (28-29), Prdx6 transgenic ( C57BL/6J-Tg(Prdx6)153Pgn/Pgn, 139 
here termed Prdx6tg/tg) mice expressing the Prdx6 sequence of the 129X1/SvJ mouse strain  140 
(30-31), and wild-type (WT) mice in the C57BL/6J genetic background were purchased from 141 
Jackson Laboratory (Bar Harbor, ME). The 129X1/SvJ sequence for Prdx6 contains an amino 142 
acid variant at position 124 encoding aspartic acid instead of alanine, leading to moderate 143 
overexpression of Prdx6 (30). Prdx6-/- and Prdx6tg/tg animals, developped normally, with no 144 
differences in survival rate and breeding performance in comparison to wildtype controls. 145 
Mice were kept under specific pathogen-free (SPF) conditions in the animal facility of the 146 
University Hospital Zurich with access to food and water ad libitum. All animal experiments 147 
were performed in accordance with institutional and state guidelines under animal experiment 148 
license No. 206/2007.54/2011. 149 
 150 
Induction of acute and chronic DSS-induced colitis 151 
Female mice received 2% DSS (MW 36 000–50 000, MP Biomedicals, Santa Ana, USA) in 152 
drinking water for 7 days for induction of acute DSS colitis and five 7-day cycles of 2% DSS 153 
interspaced with 10-day recovery phases with normal drinking water for induction of chronic 154 
DSS colitis. After the last DSS cycles animals were kept on normal drinking water for another 155 
4 weeks to investigate the then established chronic intestinal inflammation. During induction 156 
of colitis, clinical symptoms were recorded daily (weight change, animal appearance, stool 157 
appearance). At the end of the experiment (day 7 or 105), colitis severity was assessed by 158 
endoscopy and tissues sample were collected. Results represent two independent experiments 159 
with a total of n = 12 per group. 160 
 161 
Endoscopic assessment and scoring  162 
Prior to endoscopy, animals were anaesthetized i.p. with 90–120 mg ketamine (Vetoquinol 163 
AG, Bern 169 Switzerland) and 8 mg xylazine (Bayer, Lyssach, Switzerland) per kg body 164 
weight. The distal 3 cm of the colon and the rectum were examined with a Karl Storz Tele 165 
Pack Pal 20043020 (Karl Storz Endoskope, Tuttlingen, Germany). Endoscopic score was 166 
evaluated according to a scoring system (murine endoscopic index of colitis severity 167 
(MEICS)) as described previously (32).  168 
 169 
Histological assessment and scoring 170 
Histological assessment was performed on 5-μM-thick sections of the distal colon, stained 171 
with hematoxylin and eosin (H&E). Histological score was assessed by two independent 172 
blinded investigators as described previously (33):Epithelium (E) 0: normal morphology; 1: 173 
loss of goblet cells; 2: loss of goblet cells in large areas; 3: loss of crypts; 4: loss of crypts in 174 
large areas. Infiltration (I) 0: no infiltrate; 1: infiltrate around crypt basis; 2: infiltrate reaching 175 
to L. muscularis mucosae; 3: extensive infiltration reaching the L. muscularis mucosae and 176 
thickening of the mucosa with abundant oedema; 4: infiltration of the L. submucosa. The total 177 
histological score represents the sum of the epithelium and infiltration score in the distal and 178 
in the proximal colon, and thus ranges from 0 to 16 179 
(total score = (E + I)distal + (E + I)proximal). 180 
 181 
Myeloperoxidase (MPO) activity 182 
Colon tissue samples were mechanically homogenized in 50 mM phosphate buffer containing 183 
0.5 % hexadecyltrimethylammonium bromide (Sigma-Aldrich, St. Louis, MO, USA) the and 184 
Formatiert: Italienisch (Italien)
then subjected to three freeze-thaw cycles. Samples were centrifuged at 17,000 g for 2 min; 185 
and 20 µl of each supernatant was transferred in duplicate to a 96-well plate and 280 µl of 186 
0.02 % dianisidine (in 50 mM phosphate buffer and 0.0005 % H2O2; Sigma-Aldrich) were 187 
added. The absorbance was measured at 460 nm after 20 min incubation at room temperature, 188 
Protein was quantified by bicinchoninic acid assay (BCA; Pierce Biotechnology, Rockford, 189 
IL, USA) and the MPO activity (arbitrary units, U) was calculated as mean absorbance at 460 190 
nm/incubation time/protein concentration (µg/20 µl). 191 
 192 
Intestinal epithelial cells (IEC) and colonic lamina propria mononuclear cells (LPMC) 193 
isolation 194 
2/3 of the Colon were cut lengthwise, freed from residual faeces and cut into small pieces and 195 
transferred to Hank's balanced salt solution (HBSS; PAA, Linz, Austria) supplemented with 2 196 
mM of EDTA and stirred for 30 min at 37°C. Mucosal pieces were removed by passing the 197 
slurry over a coarse mesh (400 µm; Carl Roth GmbH, Karlsruhe, Germany). The sieve 198 
residue was flushed back to the tube with fresh HBSS, vigorously shaken 10 times and 199 
vortexed for 1 min for 2 times. Mucosal pieces were partitioned again from detached cells by 200 
filtration through mesh (70 µm; Falcon, Corning, MA, USA). The shake and vortex step was 201 
repeated 2 times The combined filtered fractions were collected and centrifuged at 400 g for 7 202 
min. The cell pellet – IECs -was re-suspended in  RNA isolation buffer and stored at -80°C 203 
until RNA isolation. For the LPMC isolation an enzyme cocktail (Collagenase V, 204 
0.425mgl/ml, Sigma; Collagenease D,0.75 mg/ml, Roche; Dispase, 1mg/ml Gibco; DNase 20 205 
µg/ml, Roche) was added to the supernatant followed by digestion for 15-25 min at 37°C with 206 
shaking. The cell suspension was filtered through a cell strainer (70 µm; Falcon, Corning, 207 
MA, USA). The filtered fraction was centrifuged at 400 g for 7 min, the cell pellet –LMPC – 208 
resuspended in   RNA isolation buffer and stored at -80°C until RNA isolation.  209 
 210 
RNA isolation and Real Time-qPCR  211 
RNA isolation and cDNA synthesis from human biopsies was performed as described 212 
previously (27). For RNA isolation from mouse samples colon samples of WT (n=12), Prdx6-213 
/- (n=12) and Prdx6tg/tg (n=12) mice in RLT buffer, were homogenized mechanically and total 214 
RNA was purified with the RNeasy Mini Kit in a QIACUBE operating facility (Qiagen, 215 
Venlo, Netherlands) following the manufacturer`s recommendations. 1µg total RNA was 216 
reverse-transcribed and amplified using the transcription kit from Life Technology (Carlsbad, 217 
CA, USA). The following Taqman® assays (Life Technology, Carlsbad, CA, USA) were 218 
used in combination with TaqMan® Fast Universal PCR Master Mix: PRDX6 219 
(Hs00705355_s1), VIL1 (Hs00200229_m1), Tnfa (Mm99999068_m1), Nos2 220 
(Mm01309893_m1), Ifng (Mm00801778_m1), Il6 (Mm00446190_m1), Il1b 221 
(Mm01336189_m1), Prdx3 (Mm00545844_m1), Prdx4 (Mm00450261_m1), Nrf2 222 
(Mm00477786_m1), Gss (Mm00515065_m1), Gclm (Mm00514996_m1), and Actb1 223 
(4352341E). Amplifications were performed in triplicates, and data were normalized to VIL1 224 
levels in human biopsies and to Actb1 levels in murine samples.  225 
 226 
Immunoblotting  227 
Total protein was extracted from the colon by lysing homogenized tissue in RIPA buffer 228 
(0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40) supplemented with protease inhibitors 229 
(Roche Diagnostics, Mannheim, Germany) and quantified using the BCA method. For each 230 
group, a total of 30 µg of protein was transferred to a nitrocellulose membrane after 231 
electrophoretic separation. The membrane was pre-hybridized in 5 g/L skim milk or BSA for 232 
1 h. The nitrocellulose membrane was then incubated overnight with Prdx3, Prdx4, Prdx6, 233 
Nrf2, Gss, Gclm and Gclc primary antibody. After washing in TBS, the appropriate secondary 234 
antibody conjugated to HRP was added, and the membrane was incubated at ambient 235 
temperature for 1 h. After washing in TBST again, the proteins were visualized using an ECL 236 
or ECL PLUS detection kit (Amersham, Velizy-Villacoublay, France). β-Actin was used as 237 
an internal reference control. 238 
Determination of glutathione content 239 
Total glutathione (GSH and reduced GSSG) levels were determined according to a 240 
modification of the Tietze recycling assay as described by Rahman et al.(34). In brief, 241 
deproteinized cytosolic extracts of tissue samples were obtained by mechanical 242 
homogenization in extraction buffer (0.1% Triton X-100 and 0.6% sulfosalicylic acid in 0.1M 243 
potassium phosphate buffer with 5 mM EDTA disodium salt, pH 7.5). After centrifugation at 244 
2000 rpm for 5 minutes at 4°C, the resultant supernatant was added to 120 µl of DTNB and 245 
glutathione reductase solution. 30 seconds after, 30 µl of β-NADPH was added. The 246 
absorbance of supernatant was measured at 412 nm against a reagent blank. The amount of 247 
GSH was expressed as µM/mg protein. 248 
Statistical analysis  249 
Statistical analysis was performed with the statistical software package SPSS Version 22 250 
using the Mann-Whitney rank sum test for non-parametrically distributed samples. 251 
Differences were considered significant at p < 0.05 (*), highly significant at p < 0.01 (**), and 252 
very highly significant at p < 0.001 (***). 253 
 254 
  255 
Results 256 
Prdx6-/- mice are more resistant to DSS-induced acute and chronic colitis 257 
To characterize the function of PRDX6 during intestinal inflammation, WT and Prdx6-/- mice 258 
at 8 weeks of age were administered 2% DSS in their drinking water for 7 days to induce 259 
inflammation in the large intestine. Colitis was characterized by weight loss, bloody diarrhea 260 
and inflammatory cell infiltration as previously described (35). On challenge with DSS, the 261 
onset of weight loss occurred earlier in WT mice, with 10.3 +/- 1.4 % weight loss in WT mice 262 
on day 6 in contrast to 5.4 +/- 1.5 % weight loss in Prdx6-/- mice (p = 0.0336; Figure 1A). 263 
Further, on day 7 WT mice displayed significantly more severe body weight loss in 264 
comparison to Prdx6-/- mice (WT 11.7 +/- 1.3% vs 6.3 +/- 1.7% in Prdx6-/-; p = 0.0315; Figure 265 
1A). Consistently, at autopsy, WT DSS mice showed more pronounced shortening of the 266 
large intestine in comparison to Prdx6-/- DSS mice (6.3 cm vs 7.9 cm p < 0.0001; Figure 1B). 267 
The reduced susceptibility of Prdx6-/- mice to acute DSS-induced colitis was confirmed when 268 
analyzing further parameters indicative of intestinal inflammation: MPO activity was lower in 269 
colon samples from the Prdx6-/- DSS group in comparison to the WT DSS group (145.5 U vs 270 
742.5 U p < 0.0001; Figure 1C), and the colonoscopy score was lower in Prdx6-/- DSS mice in 271 
comparison to the WT DSS group (5.1 vs 2 p = 0.0049) (Figure 1D).  Histological analysis of 272 
H&E stained colon tissue sections from WT DSS mice showed significantly more mucosal 273 
damage, loss of goblet cells and inflammatory cell infiltrate than Prdx6-/- DSS mice (12.1 vs 274 
5.9 p < 0.0001) (Figure 1E).  275 
In contrast to the marked protection from body weight loss in Prdx6-/- mice during acute 276 
colitis, no difference was found for body weight development between Prdx6-/- and WT mice 277 
after five cycles of DSS treatment (Figure 2A). Nevertheless, colon length of WT mice was 278 
significantly stronger reduced by inflammation than in Prdx6-/- mice (7.1 cm vs 8.4 cm p = 279 
0.0025; Figure 2B), and MPO activity was lower in Prdx6-/- mice when in comparison to the 280 
control group (96.25 U vs 153.2 U; p = 0.0486; Figure 2C). Endoscopic analysis of the colon 281 
as evaluated by murine endoscopic index of colitis severity (MEICS) revealed more severe 282 
inflammation in DSS treated WT mice in comparison to the Prdx6-/- DSS group (6.5 vs 3.6 p 283 
= 0.0230; Figure 2D). Consistently, histological analysis demonstrated more severe 284 
inflammation in WT than in Prdx6-/- mice: more mucosal damage, loss of goblet cells and 285 
inflammatory cell infiltration was observed in WT mice with an average score of 12.8 in WT 286 
vs 8.7 in Prdx6-/- mice (p = 0.0236; Figure 2E). Taken together, our results demonstrate that 287 
genetic ablation of Prdx6 renders mice less susceptible to DSS-induced acute and chronic 288 
colitis.  289 
 290 
Loss of Prdx6 decreases the expression of pro-inflammatory cytokines in DSS-induced 291 
acute and chronic colitis  292 
To further study the impact of loss of Prdx6 on intestinal inflammation, the expression of 293 
mRNAs coding for TNF-α, iNOS,IFN-γ IL-6 and IL-1β was analyzed. In acute colitis, Prdx6-294 
/- DSS mice showed significantly reduced expression of Tnfa (2.3 fold, p = 0.0135), Nos2 (4.6 295 
fold, p = 0.0185), Ifng (26.2 fold, p = 0.0477), ΙL6(3.9 fold, p = 0.0184) and IL1b (6.6 fold, p 296 
= 0.0109) in comparison to the WT DSS animals (Figure 1F). Consistently, in DSS-induced 297 
chronic colitis, there was a significant decrease in the expression level of Tnfa (7 fold, p = 298 
0.0450),  Nos2 (4.2 fold, p = 0.0156),  Ifng (5 fold, p = 0.0012) IL6 (7.6 fold, p = 0.0228) in 299 
Prdx6-/- DSS mice in comparison to WT DSS animals (Figure 2F). 300 
 301 
Prdx6 is downregulated in murine experimental colitis but overexpressed in human 302 
colonic biopsies of IBD patients 303 
To study how endogenous Prdx6 expression is regulated during colitis, we determined 304 
PRDX6 protein expression by Western blotting. Both wildtype as well as Prdx6tg/tg animals 305 
show significant downregulation of PRDX6 in the acute DSS colitis model (p = 0.0001 and p 306 
= 0.0136, Figure 3A, B). A similar downregulation was observed in the chronic model (Data 307 
not shown). We further analysed the mRNA expression of Prdx6 in colonic and ileal biopsies 308 
of IBD patients and controls. Interestingly, we observed a significant increase in Prdx6 309 
mRNA levels in colonic biopsies of IBD patients taken from affected tissue (Figure 3C) while 310 
ileal biopsies showed a tendency towards downregulation of Prdx6 (Figure 3D). 311 
 312 
Loss of Prdx6 induces the expression of other peroxiredoxins and antioxidant enzymes in 313 
mice exposed to acute and chronic DSS 314 
In order to understand how loss of Prdx6 exerts a protective effect during intestinal 315 
inflammation, we next analyzed the mRNA expression of other Prdx-family members such as 316 
PRDX3 and PRDX4 and antioxidant enzymes such as NRF2, GSS and GCLM in WT and 317 
Prdx6-/- mice exposed to acute or chronic DSS treatment. On challenge with acute DSS 318 
adminitstration, Prdx6-/- mice showed a significant increase in mRNA expression of Prdx3 319 
(2.31 fold, p = 0.0306), Prdx4 (1.68 fold, p = 0.0110), Nrf2 (1.92 fold, p = 0.0296) and Gss 320 
(1.69 fold, p = 0.041) in comparison to the WT DSS group (Figure 4A). The same effects 321 
were also observed upon chronic DSS-treatment: Prdx6-/- mice treated with DSS showed an 322 
increase in mRNA expression of Prdx3 (1.5 fold, p = 0.0299), Prdx4 (1.74 fold, p = 0.0219), 323 
Nrf2 (1.92 fold, p = 0.0060), Gss (2.62 fold, p < 0.0001), and Gclm (1.76 fold, p = 0.0191) 324 
(Figure 4B). However, the expression level of Prdx5 did not differ between Prdx6-/- and WT 325 
mice (data not shown).  326 
Results at mRNA level were confirmed by immunoblotting. In the acute DSS model, there 327 
was a significant increase in the expression level of Prdx3 (2.4 fold, p < 0.0001 ), Prdx4 (1.8 328 
fold, p = 0.0005), Gss (1.5 fold, p = 0.099), Gclm (1.5 fold, p < 0.0001) and Gclc (2.1 fold, p 329 
= 0.0057) (Figure 4C). In colonic mucosa of mice exposed to chronic DSS, the expression 330 
level of Prdx3 (2.3 fold, p < 0.0001), Prdx4 (1.5 fold, p < 0.0001) and Gclm (2.3 fold, p < 331 
0.0001) was significantly increased (Figure 4D).  332 
To study functional consequences of altered Gss and Gclm mRNA expression, we determined 333 
total GSH levels in colon homogenates of WT and Prdx6-/- mice exposed to DSS. In both, the 334 
acute and the chronic DSS model, total GSH levels were increased in Prdx6-/- mice in 335 
comparison to the WT DSS group (2.47 fold, p = 0.0246) and (1.87 fold, p = 0.0001; Figure 336 
4E and 4F).  337 
 338 
Increased expression of Peroxiredoxins and Nrf2 in LPMC but not in IEC 339 
To determine which cellular compartment was responsible for protection in Prdx6 knockout 340 
mice, we evaluated the mRNA expression level of antioxidant enzymes (Prdx3, Prdx4, Nrf2, 341 
Gss and Gclm) in epithelial cells and in lamina propria mononuclear cells isolated form 342 
Prdx6-/- and WT mice exposed to acute DSS colitis. No differences were observed in the 343 
expression levels of these antioxidant enzymes in epithelial cells (Figure 5A). However, we  344 
saw significant increases in the mRNA expression levels of Prdx3 (fold increase 4.3, p = 345 
0.026), Prdx4 (fold increase 1.7, p = 0.016) and Nrf2 (fold increase 2.8, p = 0.0217) in lamina 346 
propria mononuclear cells (Figure 5B). 347 
 348 
Overexpression of Prdx6 does not influence the intestinal inflammation in the acute and 349 
chronic DSS model 350 
Given the positive effect of the genetic ablation of Prdx6 in DSS induced colitis, we sought to 351 
investigate whether the overexpression of Prdx6 aggravates the outcome of colitis models. 352 
For this purpose, we used transgenic mice (Prdxgtg/tg) expressing the Prdx6 sequence of the 353 
129X1/SvJ mouse strain, and subjected them to acute and chronic DSS colitis. The 354 
129X1/SvJ sequence contains an amino acid variant at position 124 encoding aspartic acid 355 
instead of alanine, leading to moderate overexpression of Prdx6 (30). At day 7 of acute DSS 356 
treatment, animals were euthanized and body weight and colon length were measured. No 357 
differences in these parameters were found between Prdx6tg/tg and WT mice treated with DSS 358 
(Figure 6A, and B). Consistently, MPO activity, endoscopic score and histological score did 359 
not differ between Prdx6tg/tg  DSS and WT DSS animals (Figure 6C-E). Likewise, we found 360 
no differences between Prdx6tg/tg and WT mic in the chronic DSS colitis model: body weight 361 
loss (Figure 7A), colon length (Figure 7B), and MPO activity (Figure 7C) did not show any 362 
significant difference between Prdx6tg/tg DSS and WT DSS animals. Consistently, endoscopic 363 
(Figure 7D) and histologic (Figure 7E) evaluation did not show any difference between 364 
Prdx6tg/tg DSS and WT DSS mice.   365 
 366 
Cytokine expression in the colon differs in acute and chronic colitis 367 
To study the effect of Prdx6 overexpression on intestinal inflammation, mRNA expression of 368 
pro-inflammatory mediators (TNF-α, iNOS and IFN-γ) was assessed by RT-qPCR in colon 369 
tissue samples. In acute colitis, mRNAexpression of Tnfa and Ifng  in Prdx6tg/tg DSS mice 370 
were not significantly different from WT DSS mice (Figure 6F). In chronic colitis, however, 371 
Prdx6tg/tg DSS mice showed significantly lower expression of Tnfa (1.8 fold, p = 0.0190) and 372 
Ifng (10 fold, p = 0.0386) in comparison to WT DSS mice (Figure 7F).  373 
Overall, our findings show that although loss of Prdx6 protected from DSS-induced colitis, 374 
Prdx6 overexpression does not aggravate intestinal inflammation. In the chronic colitis model 375 
even lower expression of pro-inflammatory cytokines can be observed.  376 
 377 
Levels of peroxiredoxins and antioxidant enzymes in colons of WT and Prdxgtg/tg mice 378 
exposed to chronic DSS 379 
Our results suggested that Prdx6 overexpressiion did not influence the severity of DSS-380 
induced acute and chronic acoltis. However, in the chronic model, we saw a significant 381 
decrease in the expression level of TNFα and IFNγ. We therefore sought to investigate 382 
whether the overexpression of Prdx6 in the chronic model is associated with increased 383 
expression of other peroxiredoxins and antioxidant enzymes. For this purpose, we analyzed 384 
the mRNA expression of Prdx3, Prdx4, Nrf2, Gss and Gclm in WT and Prdx6tg/tg mice 385 
exposed to chronic DSS treatment. The results showed a significant increase in mRNA 386 
expression of Prdx3 (2.9 fold, p = 0.032), Nrf2 (1.52 fold, p = 0.005) and Gss (2 fold, p = 387 
0.0034) in comparison to the WT DSS group (Figure 8). 388 
  389 
Discussion  390 
As an antioxidant enzyme, PRDX6 controls the reactive oxygen species (ROS) level within 391 
cells (36). Intestinal inflammation is accompanied by massive ROS production by activated 392 
macrophages and neutrophils, which contributes to inflammation associated tissue destruction 393 
(4), hence antioxidant enzymes might play an important role during intestinal inflammation. 394 
We therefore hypothesized that knockout of Prdx6 would lead to enhanced susceptibility to 395 
DSS-induced acute and chronic intestinal inflammation, whereas overexpression of Prdx6 396 
would protect against DSS-induced colitis. Surprisingly, our results showed that genetic 397 
ablation of Prdx6 did not aggravate inflammation, but in contrast, protected animals from 398 
DSS-induced acute and chronic colitis. On challenge with DSS, Prdx6-/- mice, in comparison 399 
to WT, showed significantly less inflammation as indicated by clinical parameters and mRNA 400 
levels of pro-inflammatory cytokines. Lower inflammation was accompanied by an increase 401 
in mRNA expression of eantioxidant enzymes such as Prdx3, Prdx4, Nrf2, Gss and Gclm. 402 
Consistently, total GSH levels were increased in Prdx6 deficient mice in comparison to WT 403 
mice. Taken together, this study shows that targeted disruption of Prdx6 ameliorates colitis, 404 
associated with an increase in expression of other antioxidant enzymes and a rise in GSH 405 
levels suggesting effective compensatory mechanisms. 406 
Increased neutrophil infiltration in the colon is one of the hallmarks of pathophysiology in 407 
IBD and in the model of DSS induced experimental colitis. MPO is predominantly expressed 408 
by neutrophils thus assessment of MPO activity serves as a useful biomarker for neutrophil 409 
infiltration. Our results showed that DSS administration, as expected, increased colonic MPO 410 
activity, indicating a significant rise in neutrophil infiltration in the DSS colitis models in WT 411 
animals. Surprisingly, our data showed a significantly lower increase in MPO activity, in 412 
Prdx6-/- mice exposed to both acute and chronic DSS administration in comparison to WT 413 
animals. This lower neutrophil infiltration in Prdx6-/- animals might even be accompanied by 414 
lower ROS production, as loss of Prdx6 has been show to impair NADPH oxidase activity 415 
(37). In line with the observed differences in neutrophil infiltration, higher MEICS and 416 
histological scores indicated severe tissue damage in WT DSS animals while Prdx6-/- DSS 417 
animals showed significantly lower scores.  418 
In IBD, pro-inflammatory cytokines play an important role in the development and 419 
progression of the intestinal immune response. Accumulating data on animal models and 420 
human studies, show an increase in inflammatory cytokines, in particular TNF-α and a direct 421 
relationship between cytokine expression and extent of inflammation. TNF-α activates 422 
neutrophils and macrophages, in addition to its induction of IFN-γ production. In this study, 423 
on challenge with DSS, the mRNA expression of TNF-α, IFN-γ; Il-6 and IL1β was decreased 424 
in Prdx6-/- mice. Nitric oxide (NO), a key biomarker of oxidative stress, is synthesized by 425 
inducible nitric oxide synthase (iNOS) which is thought to be the main producer of NO in 426 
IBD (38). During inflammation, iNOS is activated and it is induced by cytokines including 427 
TNF-α, and IFN-γ. Our results showed a significant decrease in the mRNA expression level 428 
of iNOS in Prdx6-/- mice exposed to acute and chronic DSS. Taken together, our results 429 
showed that genetic ablation of Prdx6 conferred protection against DSS-induced acute and 430 
chronic colitis.  431 
As lack of Prdx6 had a beneficial effect in the investigated DSS colitis models  we next 432 
studied regulation of endogenous Prdx6 protein expression upon induction of colitis. In both 433 
the acute as well as the chronic DSS model wildtype and Prdx6tg/tg animals showed a 434 
significant downregulation of PRDX6 in line with the downregulation of PRDX6 in the acute 435 
DSS colitis model reported by Naito et al. (39). These findings suggest that no PRDX6 436 
expression is beneficial during intestinal inflammation as downregulation of Prdx6 seems to 437 
be a physiological response during in murine colitis models. 438 
In human biopsies the results are more complex. In contrast to the murine data, colonic 439 
samples showed significant upregulation of Prdx6 mRNA levels in areas affected by IBD. 440 
Ileal samples on the other hand, showed a non-significant downregulation of Prdx6 mRNA 441 
expression in IBD affected tissue similar to the regulation observed in murine samples.    442 
Previously, increased expression of PRDX6 particularly in epithelial cells of ileal samples of 443 
CD patients has been observed (40). These findings suggest that more detailed studies 444 
investigating the regulation of Prdx6 at different stages of inflammation and in different areas 445 
of the intestine are necessary to clarify the role of Prdx6 in human IBD.  446 
To address whether downregulation or lack of Prdx6 during colitis acts beneficial by allowing 447 
for compensatory upregulation of other Peroxiredoxins we determined the mRNA levels of 448 
three other 2-Cys peroxiredoxins (Prdx3, Prdx4 and Prdx5) in colon samples of Prdx6-/- and 449 
WT mice exposed to acute and chronic DSS. To date there is no report describing the role of 450 
Prdx3 and Prdx4 in IBD, however accumulating data indicate a protective role of these 451 
antioxidant enzymes in inflammation. Li et al., (41) showed that intratracheal instillation of 452 
LPS triggered higher ROS levels in macrophages and more oxidative damage to DNA and 453 
proteins in Prdx3 KO mice compared to control animals. Prdx4 was shown to protect against 454 
nonalcoholic steatohepatitis, type 2 diabetes mellitus and the metabolic syndrome by reducing 455 
oxidative stress-induced injuries (42).  In this study, the mRNA expression levels of Prdx3 456 
and Prdx4 were significantly increased in Prdx6-/- mice in comparison to WT mice. It is 457 
therefore very likely that the increased mRNA levels of Prdx3 and Prdx4 in the colon might 458 
compensate for the lack of Prdx6 and lead to enhanced antioxidant defense against DSS-459 
induced oxidative stress in the absence of Prdx6. In line with our results, two previous reports 460 
found an increase of Prdx3 and Prdx4 in Prdx6-/- mice in a hepatic ischemia/re-perfusion 461 
injury model and in cigarette smoke-mediated lung inflammatory response (25, 43). Taken 462 
together, the increase of Prdx3 and Prdx4 in the colon of Prdx6-/- mice suggests a 463 
compensatory response by other Prdx enzymes in response to acute and chronic DSS 464 
exposure. 465 
Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a redox-sensitive transcription factor 466 
orchestrating key cellular antioxidant response mechanisms. It activates a wide variety of 467 
genes encoding cytoprotective phase II detoxification and antioxidant enzymes such as 468 
glutathione synthetase (GSS), and glutamate-cysteine ligase (GCL) (44-47) via the 469 
antioxidant-responsive element promoter (44, 48). It has been documented that the lack of 470 
Nrf2 leads to a higher susceptibility to DSS-induced colitis (49) and azoxymethane/DSS 471 
colitis associated colorectal carcinoma (50). Additionally, several studies showed that the 472 
application of Nrf2 activating substances ameliorated DSS-induced acute colitis (51-52). In 473 
this study, the mRNA expression of Nrf2, Gclm and Gss was increased in Prdx6-/- animals 474 
exposed to DSS. Nrf2 can affect glutathione (GSH) synthesis, one of the most critical cellular 475 
antioxidants, by increasing the expression of Gclc and Gclm subunits and Gss (53-54). GSH is 476 
associated with reduced inflammation (55), inhibition of tumor cell growth (56), and 477 
prevention of apoptosis (57). As shown in our study, total GSH levels were increased in 478 
Prdx6-/- mice exposed to acute and chronic DSS. These results are in line with two others 479 
reports showing that in Prdx6-/- mice, the expression level of Nrf2 and the total level of GSH 480 
was increased in ethanol-mediated oxidative stress in liver and in cigarette smoke-mediated 481 
lung inflammatory response and injury models (43, 58). Taken together, it appears that a lack 482 
of Prdx6 leads to the activation of other antioxidant defense mechanisms that compensate and 483 
even overcompensate for the loss of Prdx6 during DSS-mediated intestinal inflammation. 484 
Although loss of Prdx6 had significant anti-inflammatory effects in DSS-induced colitis, its 485 
overexpression did not affect colitis severity. Due to the protective effects of Prdx6 deletion, 486 
one might expect enhanced colitis upon Prdx6 overexpression. However, the protective effect 487 
upon loss of Prdx6 seems to be due to compensatory mechanisms and seems to require 488 
enhanced expression of other peroxiredoxins. This might explain why an overexpression of 489 
Prdx6 does not have the opposite effect on colitis severity as Prdx6 deletion, in particular as 490 
we observed a likewise induction of Prdx3, Gss and Nrf2. The mechanisms how both loss as 491 
well as overexpression of Prdx6 lead to increased expression of other Peroxiredoxins and 492 
antioxidant enzymes will need to be investigated in further studies.  493 
In summary, the results of our study show, for the first time, that genetic ablation of Prdx6 494 
does not aggravate acute and chronic intestinal inflammation but is associated with increased 495 
expression of other peroxiredoxins and antioxidant enzymes/molecules, in particular Nrf2 and 496 
its target genes Gss, Gclm and GSH. Our findings suggest that maintenance of cellular redox 497 
balance during DSS-induced acute and chronic intestinal inflammation by particular 498 
peroxiredoxins and antioxidant enzymes is critical. Downregulation of Prdx6 and 499 
compensatory up-regulation of Prdx3, Prdx4, Nrf2 and enzymes of the GSH pathway seem to 500 
be a physiologic response during experimental DSS colitis..  501 
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  666 
Figure legends: 667 
Figure 1. Prdx6-/- mice are more resistant to DSS-induced acute colitis.  668 
Acute DSS colitis was induced by 2% DSS in the drinking water for seven days. Bodyweight 669 
of the animals was monitored daily and the percentage of the weight on day 0 is plotted as 670 
mean +/- (A) On day 7 colon length (B), and MPO activity on homogenized colon samples 671 
(C) were determined. Prior to euthanization, colonoscopy was performed and pictures were 672 
scored using the murine endoscopic score of colitis severity (MEICS; D). Histologic 673 
assessment was performed on H&E stained distal colon tissue sections (E). Representative 674 
pictures are shown in the right panel. (F) Level of colon pro-inflammatory mediators in 675 
WT and Prdx6-/- mice. Colon specimens of WT and KO mice after acute DSS administration 676 
and control samples were homogenized and the expression of TNF, iNOS, IFN-γ, IL-6 and IL-677 
1β was studied by real-time RT-qPCR. Results are representative of 2 independent 678 
experiments per model and values are mean ± SEM (n = 12 mice per group). * p < 0.05. 679 
 680 
Figure 2. Prdx6-/- mice are more resistant to DSS-induced chronic colitis.  681 
Chronic DSS colitis was induced by five 7-day cycles of 2% DSS (indicated in yellow) 682 
interspaced with recovery phases with normal drinking water (indicated in white). 683 
Bodyweight of the animals was monitored daily (A). Four weeks after the last DSS cycle (day 684 
105) colon length (B), and MPO activity on homogenized colon samples (C) were 685 
determined. Prior to euthanization, colonoscopy was performed and evaluated by MEICS (D). 686 
Histologic assessment was performed on H&E stained distal colon tissue sections (E). 687 
Representative pictures are shown in the right panel. (F) Level of colon pro-inflammatory 688 
mediators in WT and Prdx6-/- mice. Colon specimens of WT and KO mice after chronic 689 
DSS administration and control samples were homogenized and the expression of TNF, iNOS, 690 
IFN-γ, IL-6 and IL-1β was studied by real-time RT-qPCR. Results are representative of 2 691 
independent experiments per model and values are mean ± SEM (n = 12 mice per group). * p 692 
< 0.05; ** p < 0.01. 693 
 694 
Figure 3. Lower expression of Prdx6 in murine acute DSS colitis in contrast to 695 
overexpression in human colonic biopsies of IBD patients 696 
Analysis of Prdx6 protein expression by Western blot in C57Bl/6 wildtype (A) and Prdx6tg/tg 697 
(B) mice. Results are representative of 2 independent experiments per model with n = 12 698 
mice per group and values are given as mean ± SEM. * p < 0.05; *** p < 0.001.  699 
Total RNA was isolated from human colonic and ileal biopsies of IBD patients and controls, 700 
reversely transcribed and the expression of Prdx6 versus Vil1 was studied by real-time RT-701 
qPCR (D, E) (colon: healthy control n = 8, CD non-inflamed n = 15, CD inflamed n = 18, CD 702 
remission n = 5, UC non-inflamed n = 20, UC inflamed n = 18, UC remission n = 2; ileum: 703 
healthy control n = 13, CD non-inflamed n = 6, CD inflamed n = 4, CD remission n = 3, UC 704 
non-inflamed n = 4, UC inflamed n = 1, UC remission n = 2 705 
 706 
Figure 4. Increased mRNA and protein expression of Peroxiredoxins and antioxidant 707 
enzymes and increased GSH-levels  in Prdx6-/- mice exposed to DSS. 708 
(A and B) mRNA expression of Prdx3, Prdx4 and the antioxidant enzymes Nrf2, Gss and 709 
Gclm were determined by RT-qPCR relative to β-actin in colon tissue samples from WT and 710 
Prdx6-/- mice exposed to acute and chronic DSS. (C and D) Western blot analysis of Prdx3, 711 
Prdx4, Nrf2, Gss, Gclm and Gclc obtained from colonic samples of WT mice and Prdx6-/- 712 
mice exposed to acute and chronic DSS (E and F). Colon levels of total GSH in WT and 713 
Prdx6-/- mice exposed to acute and chronic DSS administration. Total GSH was quantified by 714 
measuring the absorbance of TNB and GS-TNB adducts at 412 nm in colon homogenates. 715 
Results are representative of 2 independent experiments per model and values are mean ± 716 
SEM (n = 12 mice per group). * p < 0.05; ** p < 0.01, *** p < 0.001. 717 
 718 
Figure 5. Increased expression of Prdx3, Nrf2 and Gss in LPMC but not in IEC  719 
Analayses of mRNA expression of Prdx3, Prdx4 and the antioxidant enzymes Nrf2, Gss and 720 
Gclm in epithelial cells and in lamina propria mononuclear cells isolated form in colon tissue 721 
samples from WT and Prdx6-/- mice exposed to acute and chronic DSS. 722 
 723 
Figure 6. Overexpression of Prdx6 does not influence the intestinal inflammation in acute 724 
DSS colitis. 725 
Acute DSS colitis was induced by 2% DSS in the drinking water for seven days. Bodyweight 726 
of the animals was monitored daily and the percentage of the weight on day 0 is plotted as 727 
mean +/- (A) On day 7 colon length (B), and MPO activity on homogenized colon samples 728 
(C) were determined. Prior to euthanization, colonoscopy was performed and pictures were 729 
scored using the murine endoscopic score of colitis severity (MEICS; D). Histologic 730 
assessment was performed on H&E stained distal colon tissue sections (E). Representative 731 
pictures are shown in the right panel. Colon specimens of WT and KO mice after acute DSS 732 
administration and control samples were homogenized and the expression of TNF, iNOS, 733 
IFN-γ, IL-6 and IL-1β was studied by real-time RT-qPCR (F). Results are representative of 2 734 
independent experiments per model and values are mean ± SEM (n = 12 mice per group)  735 
 736 
Figure 7. Overexpression of Prdx6 does not affect the inflammation in chronic DSS colitis 737 
Chronic DSS colitis was induced by five 7-day cycles of 2% DSS (indicated in yellow) 738 
interspaced with recovery phases with normal drinking water (indicated in white). 739 
Bodyweight of the animals was monitored daily (A). Four weeks after the last DSS cycle (day 740 
105) colon length (B), and MPO activity on homogenized colon samples (C) were 741 
determined. Prior to euthanization, colonoscopy was performed and evaluated by MEICS (D). 742 
Histologic assessment was performed on H&E stained distal colon tissue sections (E). 743 
Representative pictures are shown in the right panel. Colon specimens of WT and KO mice 744 
after chronic  DSS administration and control samples were homogenized and the expression 745 
of TNF, iNOS and IFN-γ was studied by real-time RT-qPCR (F). Results are representative of 746 
2 independent experiments per model and values are mean ± SEM (n = 12 mice per group). * 747 
p < 0.05 . 748 
 749 
Figure 8. Increased expression of Prdx3, Gss and Nrf2  in colons of WT and Prdxgtg/tg 750 
mice exposed to chronic DSS 751 
mRNA expression of Prdx3, Prdx4 and the antioxidant enzymes Nrf2, Gss and Gclm were 752 
determined by RT-qPCR relative to β-actin in colon tissue samples from WT and Prdx6tg/tg 753 
mice exposed to chronic DSS. 754 
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